Načítá se...
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part I
With the central importance of antiplatelet therapy in patients with coronary artery disease and the numerous positive trials with glycoprotein (GP) IIb/IIIa inhibitors given intravenously, it was hoped that one could extend the benefit of IIb/IIIa inhibition to long‐term treatment. Although the hyp...
Uloženo v:
| Vydáno v: | Clin Cardiol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Periodicals, Inc.
2006
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654758/ https://ncbi.nlm.nih.gov/pubmed/12918637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4950260803 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|